Vontobel Holding Ltd. purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,220 shares of the biotechnology company’s stock, valued at approximately $274,000.
Other large investors also recently made changes to their positions in the company. Jennison Associates LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth $347,000. Meritage Portfolio Management acquired a new position in shares of Axon Enterprise during the 4th quarter valued at about $249,000. American Trust increased its stake in shares of Axon Enterprise by 4.8% during the 3rd quarter. American Trust now owns 4,400 shares of the biotechnology company’s stock valued at $509,000 after acquiring an additional 200 shares during the last quarter. Advisor Group Holdings Inc. increased its stake in shares of Axon Enterprise by 32.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 32,121 shares of the biotechnology company’s stock valued at $5,329,000 after acquiring an additional 7,780 shares during the last quarter. Finally, Huntington National Bank increased its stake in shares of Axon Enterprise by 124.0% during the 4th quarter. Huntington National Bank now owns 1,230 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 681 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.
Insider Buying and Selling
In related news, CFO Brittany Bagley purchased 250 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was acquired at an average price of $200.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief financial officer now owns 109,174 shares in the company, valued at $21,834,800. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Julie A. Cullivan sold 2,013 shares of Axon Enterprise stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $197.58, for a total value of $397,728.54. Following the completion of the transaction, the director now directly owns 7,062 shares in the company, valued at $1,395,309.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brittany Bagley acquired 250 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, May 17th. The shares were purchased at an average price of $200.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief financial officer now directly owns 109,174 shares of the company’s stock, valued at $21,834,800. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 45,250 shares of company stock worth $8,735,200 and sold 4,675 shares worth $920,785. Insiders own 6.10% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. TheStreet cut shares of Axon Enterprise from a “b-” rating to a “c+” rating in a research note on Friday, May 26th. StockNews.com began coverage on shares of Axon Enterprise in a research note on Thursday, May 18th. They set a “hold” rating for the company. The Goldman Sachs Group began coverage on Axon Enterprise in a research note on Tuesday, March 7th. They issued a “buy” rating and a $263.00 price objective on the stock. JPMorgan Chase & Co. raised Axon Enterprise from a “neutral” rating to an “overweight” rating and set a $236.00 price objective on the stock in a research note on Thursday, May 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Axon Enterprise in a research note on Thursday, April 13th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $232.64.
Axon Enterprise Trading Down 0.4 %
NASDAQ:AXON opened at $195.12 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.97 and a current ratio of 3.33. Axon Enterprise, Inc. has a one year low of $88.61 and a one year high of $229.95. The business’s 50-day simple moving average is $198.06 and its 200 day simple moving average is $202.38. The stock has a market cap of $14.42 billion, a price-to-earnings ratio of 103.24 and a beta of 0.92.
Axon Enterprise (NASDAQ:AXON – Free Report) last released its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.03 by $0.48. The business had revenue of $343.04 million for the quarter, compared to analysts’ expectations of $312.07 million. Axon Enterprise had a return on equity of 10.65% and a net margin of 10.76%. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 1.58 earnings per share for the current fiscal year.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
